ARGXClinical Trialsglobenewswire

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

Sentiment:Positive (75)

Summary

August 25, 2025, 7:00 AM CET

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 25, 2025 by globenewswire

    argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG | ARGX Stock News | Candlesense